Hypertension and Diabetes Mellitus

Hypertension: A Companion to Braunwald's Heart Disease

Volumn , Issue , 2007, Pages 406-417

  Mugo, Maryann N ^a   Stump, Craig S ^a,b   Rao, Priya G ^a   Sowers, James R ^a  

^a University of Missouri   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882912327     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-3053-9.50040-8     Document Type: Chapter

References (76)

1. American Diabetes Association National Diabetes Fact Sheet http://www.diabetes.org/uedocuments/NationalDiabetesFactSheetRev.pdf.
2. Ogden CL, Flegal KM, Carroll MD, Johnson CL Prevalence and trends in overweight among U.S. children and adolescents, 1999-2000. JAMA 2002, 288:1728-1732.
3. Sowers JR, Epstein M, Frohlich ED Diabetes, hypertension, and cardiovascular disease: An update. Hypertension 2001, 37:1053-1059.
4. Gress TW, Nieto FJ, Shahar E, et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus: Atherosclerosis Risk in Communities Study. N Engl J Med 2000, 342:905-912.
5. Sowers JR Treatment of hypertension in patients with diabetes. Arch Intern Med 2004, 164:1850-1857.
6. Perkins BA, Ficociello LH, Silva KH, et al. Regression of microalbuminuria in type 1 diabetes. N Engl J Med 2003, 348:2285-2293.
7. Sowers JR, Williams M, Epstein M, et al. Hypertension in patients with diabetes: Strategies for drug therapy to reduce complications. Postgrad Med 2000, 107:47-54. 60.
8. Grundy SM, Brewer HB, Cleeman JI, et al. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004, 109:433-438.
9. Ford ES, Giles WH, Mokdad AH Increasing prevalence of the metabolic syndrome among U.S. Adults. Diabetes Care 2004, 27:2444-2449.
10. Stamler J, Stamler R, Neaton JD Blood pressure, systolic and diastolic, and cardiovascular risks. US population data. Arch Intern Med 1993, 153:598-615.
11. United Kingdom Prospective Diabetes Study Group Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998, 317:703-713.
12. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998, 351:1755-1762.
13. Tuomilehto J, Rastenyte D, Birkenhager WH, et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension: Systolic Hypertension in Europe Trial Investigators. N Engl J Med 1999, 340:677-684.
14. Sowers JR Stroke in patients with diabetes. J Clin Hypertens 2004, 6:63.
15. Bell DS Stroke in the diabetic patient. Diabetes Care 1994, 17:213-219.
16. Sacco RL Reducing the risk of stroke in diabetes: What have we learned that is new?. Diabetes Obes Metab 2002, 4(Suppl 1):S27-S34.
17. Heart Outcomes Prevention Evaluation Study Investigators Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Lancet 2000, 355:253-259.
18. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002, 359:995-1003.
19. Lindholm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint Reduction in Hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002, 359:1004-1010.
20. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288:2981-2997. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group.
21. Sowers JR Insulin resistance and hypertension. Am J Physiol 2004, 286:H1597-H1602.
22. McFarlane SI, Banerji M, Sowers JR Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab 2001, 86:713-718.
23. Padwal R, Laupacis A Antihypertensive therapy and incidence of type 2 diabetes: A systematic review. Diabetes Care 2004, 27:247-255.
24. Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes: A consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000, 36:646-661.
25. US Renal Data System. USRDS 2005. Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: National Institute of Health, National Institute of Diabetes and Digestive and Kidney Disease.
26. Eknoyan G, Hostetter T, Bakris GL, et al. Proteinuria and other markers of chronic kidney disease: A position statement of the National Kidney Foundation (NKF) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Am J Kidney Dis 2003, 42:617-622.
27. Gerstein HC, Mann JF, Pogue J, et al. Prevalence and determinants of microalbuminuria in high-risk diabetic and nondiabetic patients in the Heart Outcomes Prevention Evaluation Study: The HOPE Study Investigators. Diabetes Care 2000, 23(Suppl 2):B35-B39.
28. Sowers JR, Haffner S Treatment of cardiovascular and renal risk factors in the diabetic hypertensive. Hypertension 2002, 40:781-788.
29. Chobanian AV, Bakris GL, Black HR, the National High Blood Pressure Education Program Coordinating Committee, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 2003, 289:2560-2572.
30. Sowers JR Obesity as a cardiovascular risk factor. Am J Med 2003, 115(Suppl 8A):37S-41S.
31. Wassertheil-Smoller S, Blaufox MD, Oberman AS, et al. The Trial of Antihypertensive Interventions and Management (TAIM) study: Adequate weight loss, alone and combined with drug therapy in the treatment of mild hypertension. Arch Intern Med 1992, 152:131-136.
32. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001, 344:1343-1350.
33. Hu G, Barengo NC, Tuomilehto J, et al. Relationship of physical activity and body mass index to the risk of hypertension: A prospective study in Finland. Hypertension 2004, 43:25-30.
34. Whelton SP, Chin A, Xin X, et al. Effect of aerobic exercise on blood pressure: A meta-analysis of randomized, controlled trials. Ann Intern Med 2002, 136:493-503.
35. McFarlane SI, Jacober SJ, Winer N, et al. Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centers. Diabetes Care 2002, 25:718-723.
36. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342:145-153.
37. Niskanen L, Hedner T, Hansson L, et al. Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based treatment regimen: A subanalysis of the Captopril Prevention Project. Diabetes Care 2001, 24:2091-2096.
38. Bakris GL, Smith AC, Richardson DJ, et al. Impact of an ACE inhibitor and calcium antagonist on microalbuminuria and lipid subfractions in type 2 diabetes: A randomised, multicentre pilot study. J Hum Hypertens 2002, 16:185-191.
39. Ravid M, Lang R, Rachmani R, et al. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus: A 7-year follow-up study. Arch Intern Med 1996, 156:286-289.
40. Bakris GL, Weir MR Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: Is this a cause for concern?. Arch Intern Med 2000, 160:685-693.
41. Scheen AJ Renin-angiotensin system inhibition prevents type 2 diabetes mellitus: Part 1. A meta-analysis of randomised clinical trials. Diabetes Metab 2004, 30:487-496.
42. Sowers JR Treatment of hypertension in patients with diabetes. Arch Intern Med 2004, 164:1850-1857.
43. Bakris GL, Weir MR, Shanifar S, et al. Effects of blood pressure level on progression of diabetic nephropathy: Results from the RENAAL study. Arch Intern Med 2003, 163:1555-1565.
44. Mogensen CE, Neldam S, Tikkanen I, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The Candesartan and Lisinopril Microalbuminuria (CALM) study. BMJ 2000, 321:1440-1444.
45. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic. JAMA 2002, 288:2981-2997. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group.
46. Verdecchia P, Reboldi G, Angeli F, et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004, 43:963-969.
47. Bakris GL, Sowers JR When does new onset diabetes resulting from antihypertensive therapy increase cardiovascular risk?. Hypertension 2004, 43:941-942.
48. Kostis JB, Lawrence-Nelson J, Ranjan R, et al. Association of increased pulse pressure with the development of heart failure in SHEP: Systolic Hypertension in the Elderly (SHEP) Cooperative Research Group. Am J Hypertens 2001, 14:798-803.
49. Black HR, Elliott WJ, Neaton JD, et al. Baseline characteristics and early blood pressure control in the CONVINCE trial. Hypertension 2001, 37:12-18.
50. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs. a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease: The International Verapamil-Trandolapril Study (INVEST). A randomized controlled trial. JAMA 2003, 290:2805-2816.
51. Birkenhager WH, Staessen JA, Gasowski J, et al. Effects of antihypertensive treatment on endpoints in the diabetic patients randomized in the Systolic Hypertension in Europe (Syst-Eur) trial. J Nephrol 2000, 13:232-237.
52. Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): Prospective observational study. BMJ 2000, 321:412-419.
53. Carlberg B, Samuelsson O, Lindholm LH Atenolol in hypertension: Is it a wise choice?. Lancet 2004, 364:1684-1689.
54. Jacob S, Balletshofer B, Henriksen EJ, et al. Beta-blocking agents in patients with insulin resistance: Effects of vasodilating beta-blockers. Blood Press 1999, 8:261-268.
55. Fassbinder W, Quarder O, Waltz A Treatment with carvedilol is associated with a significant reduction in microalbuminuria: A multicentre randomised study. Int J Clin Pract 1999, 53:519-522.
56. Khoury AF, Kaplan NM Alpha-blocker therapy of hypertension: An unfulfilled promise. JAMA 1991, 266:394-398.
57. Ohkubo T, Hozawa A, Yamaguchi J, et al. Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure: The Ohasama study. J Hypertens 2002, 20:2183-2189.
58. Fang ZY, Prins JB, Marwick TH Diabetic cardiomyopathy: Evidence, mechanisms, and therapeutic implications. Endocr Rev 2004, 25:543-567.
59. Sowers JR Insulin and insulin-like growth factor in normal and pathological cardiovascular physiology. Hypertension 1997, 229:691-699.
60. Sowers JR Insulin resistance and hypertension. Mol Cell Endocrinol 1990, 74:C87-C89.
61. Savage PJ, Pressel SL, Curb JD, et al. Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: The Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. Arch Intern Med 1998, 158:741-751.
62. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999, 353:611-616.
63. Black HR, Elliott WJ, Grandits G, et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 2003, 289:2073-2082.
64. Barzilay JJ, Pressel S, Davis BR Risks and impact of incident glucose disorder in hypertensive older adults treated with an ACE inhibitor, a diuretic, or a calcium channel blocker: A report from the ALLHAT trial [abstract]. Am J Hypertens 2004, 17:1A.
65. McFarlane SI, Kumar A, Sowers JR Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease. Am J Cardiol 2003, 91:30H-37H.
66. Vermes E, Ducharme A, Bourassa MG, et al. Enalapril reduces the incidence of diabetes in patients with chronic heart failure: Insight from the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 2003, 107:1291-1296.
67. Braunwald E, Domanski MJ, Fowler SE, et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004, 351:2058-2068.
68. Lindholm LH, Ibsen H, Borch-Johnsen K, et al. Risk of new-onset diabetes in the Losartan Intervention for Endpoint Reduction in Hypertension study. J Hypertens 2002, 20:1879-1886.
69. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM-Overall programme. Lancet 2003, 362:759-766.
70. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved trial. Lancet 2003, 362:777-781.
71. Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): Principal results of a randomized double-blind intervention trial. J Hypertens 2003, 21:875-886.
72. Lindholm LH, Persson M, Alaupovic P, et al. Metabolic outcome during 1 year in newly detected hypertensives: Results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens 2003, 21:1563-1574.
73. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet 2004, 363:2022-2031.
74. Califf RM, Holman R People at increased risk of cardiovascular disease screened for the NAVIGATOR trial subsequently have undiagnosed diabetes or impaired glucose tolerance [abstract]. J Am Coll Cardiol 2003, 21:531.
75. Yusuf S From the HOPE to the ONTARGET and the TRANSCEND studies: Challenges in improving prognosis. Am J Cardiol 2002, 89:18A-26A.
76. Teo K, Yusuf S, Anderson C, et al. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J 2004, 148:52-61.